ACHIEVE: Oral Orforglipron in Type 2 Diabetes (2026)

If you searched for the "QWINT" trial of oral orforglipron in type 2 diabetes, here is the first thing worth knowing: the pivotal phase 3 program for orforglipron is actually named ACHIEVE (ACHIEVE-1 through ACHIEVE-5), not QWINT. "QWINT" is a different Eli Lilly program entirely — it tests the once-weekly insulin efsitora alfa, not a GLP-1 pill. The two get conflated because both are Lilly diabetes programs that read out around the same time. So this deep-dive walks through the trials people mean when they ask about orforglipron in diabetes: the ACHIEVE phase 3 set. Orforglipron is a non-peptide, small-molecule, once-daily oral GLP-1 receptor agonist — the molecule marketed as Foundayo — taken with no food or water restrictions. In ACHIEVE-1, it lowered HbA1c by up to 1.6 percentage points from a baseline of 8.0% and cut body weight by up to 7.9% over 40 weeks (Rosenstock 2025 ^[1]). Here is the full data walkthrough, the head-to-head against oral semaglutide, the GI safety picture, and how it stacks up against injectable GLP-1s.

The honest summary

• The program is ACHIEVE, not QWINT. Orforglipron's five-trial phase 3 diabetes program is named ACHIEVE. QWINT is Lilly's separate once-weekly insulin (efsitora alfa) program — a common mix-up, but a different drug and class.
• ACHIEVE-1 is the anchor trial. 559 adults with early type 2 diabetes managed by diet and exercise alone; orforglipron 3/12/36 mg vs placebo for 40 weeks. HbA1c fell 1.3-1.6% vs 0.1% on placebo, from a baseline of 8.0% (Rosenstock 2025^[1]).
• Most people hit target. 61-66% of orforglipron participants reached HbA1c at or below 6.5% versus 13.5% on placebo (Rosenstock 2025^[1]).
• Meaningful weight loss alongside glucose control. At 36 mg, average weight loss was 7.3 kg (16.0 lb), or 7.9%, versus 1.6% on placebo (Rosenstock 2025^[1]).
• It beat oral semaglutide head-to-head. In ACHIEVE-3 (1,698 adults on metformin), orforglipron 36 mg lowered HbA1c 2.2% and weight 9.2% vs 1.4% and 5.3% for oral semaglutide 14 mg (Rosenstock 2026, Lancet^[2]).
• The side-effect profile is classic GLP-1. Mostly GI — nausea, diarrhea, constipation, vomiting — front-loaded during dose escalation. Discontinuations for adverse events ran 4-8% across orforglipron doses vs 1% on placebo in ACHIEVE-1 (Rosenstock 2025^[1]).
• The pill convenience is the headline. No injection, no fasting, no water timing — unlike oral semaglutide (Rybelsus), which requires an empty stomach and strict water rules.

First, clearing up QWINT vs ACHIEVE

Because this article exists to answer a real search, it is worth being precise. QWINT is the phase 3 program for insulin efsitora alfa, Lilly's investigational once-weekly basal insulin — trials such as QWINT-1, QWINT-2, QWINT-3 and QWINT-4 compared weekly efsitora against daily basal insulins like glargine and degludec in type 2 diabetes (Bue-Valleskey 2025^[3]). That is an insulin program, not a GLP-1 program.

Orforglipron — the oral GLP-1 pill — is tested in the ACHIEVE program: a set of global phase 3 registration trials enrolling more than 6,000 adults with type 2 diabetes. ACHIEVE-1 (monotherapy vs placebo), ACHIEVE-2 (vs the SGLT2 inhibitor dapagliflozin on metformin), ACHIEVE-3 (head-to-head vs oral semaglutide), ACHIEVE-4 (vs basal insulin glargine, with a cardiovascular safety read), and ACHIEVE-5 (added to titrated insulin glargine). If you came here for "the QWINT orforglipron diabetes trial," you mean ACHIEVE. The rest of this piece is that walkthrough.

ACHIEVE-1: the anchor trial, in detail

The headline diabetes result was published in The New England Journal of Medicine in 2025 (Rosenstock 2025^[1]). ACHIEVE-1 was a phase 3, randomized, double-blind, placebo-controlled trial that enrolled 559 adults across the United States, China, India, Japan and Mexico. Participants had relatively early type 2 diabetes managed with diet and exercise alone, a baseline HbA1c of at least 7.0% but no more than 9.5%, and a body-mass index of at least 23. They were randomized 1:1:1:1 to orforglipron 3 mg, 12 mg, or 36 mg once daily, or matching placebo, for 40 weeks.

Blood sugar (HbA1c)

From a mean baseline of 8.0%, HbA1c fell by approximately 1.3% on 3 mg, 1.6% on 12 mg, and 1.5% on 36 mg, versus just 0.1% on placebo (efficacy estimand). Improvements appeared as early as four weeks. The proportion of participants reaching an HbA1c at or below the 6.5% target — essentially the threshold below the diabetes range — was 61.5% (3 mg), 62.3% (12 mg), and 66.0% (36 mg) versus only 13.5% on placebo (Rosenstock 2025^[1]). A reduction of roughly 1.5 percentage points from a baseline of 8.0% is clinically substantial — it is the kind of drop that moves many people from uncontrolled diabetes toward the recommended range.

Body weight

Weight loss tracked with dose. From a baseline body weight near 90 kg (about 199 lb), average reductions were 4.4 kg (9.7 lb, 4.7%) on 3 mg, 5.5 kg (12.2 lb, 6.1%) on 12 mg, and 7.3 kg (16.0 lb, 7.9%) on 36 mg, versus 1.3 kg (2.9 lb, 1.6%) on placebo (Rosenstock 2025^[1]). This is notable because ACHIEVE-1 enrolled a diabetes population, not a dedicated obesity population — weight loss in diabetes trials is typically more modest than in pure obesity trials. (For the obesity side of the molecule, the separate ATTAIN-1 trial reported about 12.4% weight loss at the top dose over 72 weeks; Wharton 2025^[4].)

Safety and tolerability

The adverse-event profile was the familiar GLP-1 pattern, dominated by gastrointestinal effects that were generally mild to moderate and concentrated during dose escalation. In ACHIEVE-1, rates across the 3/12/36 mg arms versus placebo were: diarrhea 19%/21%/26% vs 9%, nausea 13%/18%/16% vs 2%, constipation 8%/17%/14% vs 4%, and vomiting 5%/7%/14% vs 1%. Discontinuation due to adverse events ran 6% (3 mg), 4% (12 mg) and 8% (36 mg) versus 1% on placebo (Rosenstock 2025^[1]). Lilly characterized the overall safety profile as consistent with the injectable GLP-1 class — an important framing, because it means switching from a needle to a pill does not appear to introduce a new safety category.

ACHIEVE-3: orforglipron beat oral semaglutide head-to-head

The most commercially important readout was the direct comparison against the existing oral GLP-1, oral semaglutide (Rybelsus). ACHIEVE-3, published in The Lancet in 2026 (Rosenstock 2026^[2]), was a 52-week, open-label, randomized phase 3 trial of 1,698 adults with type 2 diabetes inadequately controlled on metformin. Participants were randomized 1:1:1:1 to orforglipron 12 mg or 36 mg, or oral semaglutide 7 mg or 14 mg.

Orforglipron 36 mg lowered HbA1c by about 2.2% versus 1.4% for the top oral semaglutide dose, and cut weight by about 9.2% versus 5.3% — meeting non-inferiority and then demonstrating superiority on key endpoints (Rosenstock 2026^[2]). The trade-off: gastrointestinal events, discontinuations due to adverse events, and the average increase in pulse rate were higher with orforglipron than with oral semaglutide. So the head-to-head story is "more efficacy, somewhat more GI burden" — plus the convenience edge of no food or water restrictions. For a consumer-level comparison of the oral options, see oral GLP-1 pills compared.

The rest of the ACHIEVE program

• ACHIEVE-2 (vs dapagliflozin): in adults inadequately controlled on metformin, orforglipron produced larger HbA1c reductions (up to roughly 1.7%) than the SGLT2 inhibitor dapagliflozin 10 mg (around 0.8%), with greater weight loss — positioning it as a strong second-line oral option (Lilly ACHIEVE-2/-5 readout^[5]).
• ACHIEVE-5 (added to insulin glargine): when added on top of titrated basal insulin (with or without metformin and/or an SGLT2 inhibitor), orforglipron drove an additional HbA1c reduction of roughly 2.1% versus placebo, meeting its primary endpoint — relevant for people whose diabetes is advanced enough to need insulin (Lilly ACHIEVE-2/-5 readout^[5]).
• ACHIEVE-4 (vs basal insulin glargine): the largest and longest trial, randomizing more than 2,700 adults across 15 countries to orforglipron or treat-to-target insulin glargine. It was designed with a cardiovascular safety component; the reported MACE hazard ratio of 0.84 (95% CI 0.59-1.20) was consistent with non-inferiority for cardiovascular safety versus insulin (Lilly ACHIEVE-4 readout^[6]).
• ACHIEVE-1 (monotherapy): the anchor trial detailed above (Rosenstock 2025^[1]).

Taken together, the program tested orforglipron across the full diabetes-treatment ladder — alone, against another oral pill, against the standard oral GLP-1, added to insulin, and against insulin itself — which is exactly the breadth regulators expect before approving a drug as a foundational diabetes therapy.

How it compares to injectable GLP-1s and oral semaglutide

The clinical appeal of orforglipron is that it delivers GLP-1-class glucose and weight benefits in a once-daily pill with no injection and no dosing rituals. Against injectable semaglutide (Ozempic) and tirzepatide (Mounjaro), the ACHIEVE HbA1c reductions (roughly 1.5-2.2% depending on trial and dose) sit within the range those injectables achieve, though tirzepatide — a dual GIP/GLP-1 agonist — generally produces the largest weight loss of the class. Orforglipron's edge is not raw potency over the strongest injectable; it is removing the needle while staying in the same efficacy neighborhood.

Against oral semaglutide (Rybelsus) — the only other oral GLP-1 — ACHIEVE-3 showed orforglipron was the stronger pill on both HbA1c and weight, with the convenience advantage of no empty-stomach or water restrictions, at the cost of somewhat more GI side effects (Rosenstock 2026^[2]). For people who want a pill rather than an injection, that head-to-head is the single most decision-relevant piece of evidence. For a broader look at where orforglipron fits against next-generation molecules, see retatrutide vs orforglipron.

What this means if you are weighing orforglipron

• It is a genuinely effective oral GLP-1 for type 2 diabetes. Across ACHIEVE, it lowered HbA1c by roughly 1.5-2.2% and produced meaningful weight loss, with most participants reaching target glucose levels (Rosenstock 2025^[1]; Rosenstock 2026^[2]).
• Expect GI side effects early. Nausea, diarrhea, constipation and vomiting are common during dose escalation and tend to ease over time. Discontinuation rates were modest (4-8%) but real (Rosenstock 2025^[1]).
• The pill convenience is the differentiator. No injection, no fasting, no water timing — a real advantage over oral semaglutide's strict dosing rules.
• It is not a substitute for medical care. Diabetes drug selection depends on your HbA1c, weight goals, kidney and heart status, other medications, and cost. These trial averages describe groups, not your individual response.
• Talk to your prescriber. If a once-daily oral GLP-1 sounds appealing, the ACHIEVE data are a reason to ask about it — not a reason to self-prescribe or buy from unverified sources.

Bottom line

The trial program people search for as "QWINT orforglipron" is really the ACHIEVE program (QWINT tests Lilly's weekly insulin, a different drug). In ACHIEVE-1, the once-daily oral GLP-1 pill orforglipron lowered HbA1c by up to 1.6 percentage points from a baseline of 8.0% and cut body weight by up to 7.9% over 40 weeks, with 61-66% of users reaching target glucose (Rosenstock 2025^[1]). In the head-to-head ACHIEVE-3 trial it outperformed oral semaglutide on both HbA1c (2.2% vs 1.4%) and weight (9.2% vs 5.3%), at the cost of somewhat more GI side effects (Rosenstock 2026^[2]). Side effects are the standard GLP-1 GI cluster, mostly during titration. The molecule — marketed as Foundayo — offers injectable-class results in a pill with no food or water restrictions, which is its central appeal. As always, drug selection is a decision for you and your prescriber.

This article is educational and is not medical advice. Every trial name, HbA1c figure, weight-loss figure, and adverse-event rate above is sourced to a peer-reviewed publication (NEJM, The Lancet) or a primary Eli Lilly clinical readout, verified against the live PubMed database before publication. The orforglipron diabetes program is named ACHIEVE; "QWINT" is Lilly's separate once-weekly insulin efsitora alfa program. Discuss any diabetes treatment decision with your own clinician.